Bird H A, Hill J, Dixon J S, Looi D, Wright V
Eur J Rheumatol Inflamm. 1985;8(1):53-9.
Tenoxicam (TILCOTIL, MOBIFLEX) 40 mg/day has been compared to piroxicam 40 mg/day in a double-blind, parallel group study of 4 weeks duration in 30 patients with osteoarthrosis. Both drugs were well tolerated, tenoxicam slightly better than piroxicam. Both drugs improved general pain, improvement being greater with tenoxicam. Little improvement of other symptoms was seen with either treatment. At the end of the study, 12 tenoxicam-treated patients and seven piroxicam-treated patients elected to remain on their respective treatment.
在一项针对30名骨关节炎患者进行的为期4周的双盲平行组研究中,对替诺昔康(痛灭定、莫比可)每日40毫克与吡罗昔康每日40毫克进行了比较。两种药物耐受性均良好,替诺昔康略优于吡罗昔康。两种药物均改善了总体疼痛,替诺昔康的改善效果更明显。两种治疗方法对其他症状的改善均不明显。研究结束时,12名接受替诺昔康治疗的患者和7名接受吡罗昔康治疗的患者选择继续接受各自的治疗。